[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
December 12, 2001

Cardiovascular Events and COX-2 Inhibitors

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(22):2808-2813. doi:10.1001/jama.286.22.2808

To the Editor: Dr Mukherjee and colleagues1 did not include all selective COX-2 agents in their meta-analysis. Meloxicam is a COX-2 selective inhibitor2 that has been used by more than 45 million patients in more than 100 countries worldwide. The National Institute for Clinical Excellence of the United Kingdom included meloxicam with celecoxib and rofecoxib in their review of the selective COX-2 inhibitors.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×